NCT06725719 is a clinical trial of 18F-DPA714/FDPA in Neuroinflammation, sponsored by Tianjin Medical University.

Who is sponsoring NCT06725719?

NCT06725719 is sponsored by Tianjin Medical University.

What drugs are being tested in NCT06725719?

Interventions in NCT06725719: 18F-DPA714/FDPA.

What condition does NCT06725719 study?

NCT06725719 studies Neuroinflammation, Stroke, Neurodegenerative Diseases.

Is NCT06725719 still recruiting?

NCT06725719 is currently recruiting now. Last updated 11 February 2025.

Last reviewed 2025-02-11 · How we verify

NCT06725719

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Translocator Protein PET/CT in Various TSPO-Related Disease

Recruiting now Last updated 11 February 2025

What this trial tests

trial testing 18F-DPA714/FDPA in Neuroinflammation in 200 participants. Currently enrolling.

Timeline

1 November 2018

Primary endpoint
1 December 2027

1 December 2027

Quick facts

Lead sponsor	Tianjin Medical University
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	200
Start date	1 November 2018
Primary completion	1 December 2027
Estimated completion	1 December 2027
Sites	2 locations across China

Drugs / interventions tested

18F-DPA714/FDPA

Conditions studied

Neuroinflammation — all drugs for Neuroinflammation →
Stroke — all drugs for Stroke →
Neurodegenerative Diseases — all drugs for Neurodegenerative Diseases →

Sponsor

Tianjin Medical University

Who can join

Adults 18 to 80, any sex, with Neuroinflammation or Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the potential usefulness of 18F-DPA714/FDPA positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various TSPO-related disease patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Neuroinflammation

Currently open trials in the same condition.

NCT06391866 — Neuroinflammation/Oxidative Stress/Cardiac Surgery · recruiting
NCT06432023 — Imaging - Clinical Evaluation of Altered Nervous System Drainage · recruiting

Other Tianjin Medical University trials

Trials by the same sponsor.

NCT07393685 — Effectiveness of Xuanfei Jiangzhuo Decoction for Influenza-Induced AECOPD · not yet recruiting
NCT07306598 — [18F]NIDF PET Imaging in Tau-related Diseases · recruiting
NCT07232459 — [18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis · recruiting
NCT06949670 — Alpha-Synuclein PET/CT in Various α-Syn-Related Disease · recruiting
NCT06628531 — ALI & Pulmonary HA Deposition After SAH · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06725719 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tianjin Medical University
Last refreshed: 11 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06725719.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing